COVID-19: Pfizer Coronavirus Vaccine Shows Positive Results in Human Trials

| |

The American Pharmacist Pfizer and the german firm BioNTech on Wednesday they announced positive results in their initial human trials with the vaccine for him coronavirus in which they are working. The study included 45 adults between the ages of 18 and 55 and tested different doses of the vaccine that, according to the companies, produced antibodies higher than those of patients who have recovered from the vaccine. COVID-19.

In a statement, Pfizer’s head of vaccine research and development, Kathrin Jansen, said the clinical data is positive and that the work is being carried out with the utmost urgency.

The vaccine, according to the note, was generally well tolerated, although in some cases it caused fevers and local pain where it was injected, but without any serious reaction being detected. The two companies now plan to use the information gathered to conduct a much larger test, with up to 30,000 participants, and which they hope to start in late July if the go-ahead from regulators is received.

They would produce millions of doses
Pfizer and BioNTech presented the data from their first study for peer review and for publication in a scientific journal. The companies indicated that if the rest of the tests are successful and the vaccine receives regulatory approval, they intend to manufacture up to 100 million doses in the remainder of the year and potentially more than 1.2 billion in 2021.

Shares of Pfizer, a New York-based industry giant, rose sharply on Wall Street on Wednesday following the announcement. This vaccine is in addition to several others in which other pharmaceutical companies in various countries are working and which have also obtained promising results in the first tests with humans.

At the moment, the widespread use of any coronavirus vaccine has not been approved, which has left more than half a million deaths worldwide and more than 10.5 million confirmed cases. Typically, the period for a vaccine to be available for use at a mass level is at least 12 to 18 months, according to the World Health Organization (WHO), although in this case there is an expectation that the process can be accelerated.

With information from EFE

LEE: China: Sinopharm redoubles its coronavirus vaccine production capacity

LEE: Russia: Three Prototypes of Coronavirus Vaccine Show Efficacy



Rain forecast for Neptune and Uranus. The good news is that they are diamonds

In Mexico they report that the Mazatlán FC roster is complete and include Jorge Valdivia


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.